P R O G R A M

PNS ANNUAL MEETING

2018

BALTIMORE
MARYLAND

21-25 JULY

Renaissance Baltimore Harborplace Hotel

Connect with PNS

www.pnsociety.com
On Behalf of the Peripheral Nerve Society, we are delighted to welcome you to the 2018 Annual Meeting at the Renaissance Baltimore Harborplace Hotel in Baltimore, Maryland, USA.

The PNS Annual Meeting continues to be the premier meeting for cutting-edge innovation and advances in peripheral neuropathy. The 2018 meeting will provide the usual mixture of excellent plenary lectures, oral platforms, oral posters and poster sessions. This year we have added parallel sessions on Sunday and Monday afternoon organized by special interest groups Inflammatory Neuropathy Consortium (INC), Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR) and the Diabetic Neuropathy Consortium. There will also be dedicated clinical trials sessions. We look forward to you being part of it.

Please join us for the Opening Ceremony on Saturday evening at the Maryland Science Center. The reception will feature complimentary drinks and hors d’oeuvres.

Coffee breaks and lunch will be provided daily for delegates. Please see the program for additional details. Complimentary internet will also be provided. Instructions for access can be found on page 10 of the program.

Be sure to attend the PNS Annual General Meeting on Monday at 12:30 in Maryland Ballroom ABCD. We will be reviewing Society business, and your input is needed. All are encouraged to attend.

Sunday night, all are invited to join, as we honor Junior and new Members of the Society with a reception at the hotel. Monday evening, the PNS will have another all member reception to maximize your networking time with your colleagues.

Before you depart, please join us for a unique and fun PNS Closing Reception at Camden Yards, where we will watch an Orioles vs Red Sox Baseball Game. Transportation will be provided to and from the hotel.

I want to personally thank the Scientific Program Committee, PNS Board, Meeting Faculty, and everyone else who has generously donated their time and efforts to put together this outstanding meeting.

I hope you enjoy the 2018 PNS Annual Meeting and your stay in Baltimore.

Steven S. Scherer, MD, PhD
Peripheral Nerve Society President
OFFICERS
Steven S. Scherer - President, Philadelphia, Pennsylvania, USA
Pieter Van Doorn - President-Elect, Rotterdam, Netherlands
Michael Polydefkis - Secretary/Treasurer, Baltimore, Maryland, USA
Mary M. Reilly - Past President, London, United Kingdom

BOARD MEMBERS
David Adams, Le Kremlin Bicetre, France
Alessandra Bolino, Milan, Italy
Chiara Briani, Padova, Italy
Satoshi Kuwabara, Chiba, Japan
Ingemar Merkies, Rotterdam, Netherlands
Kasim Sheikh, Houston, Texas, USA

INFLAMMATORY NEUROPATHY CONSORTIUM REPRESENTATIVE
Richard Lewis, Los Angeles, California, USA

DIABETIC NEUROPATHY CONSORTIUM REPRESENTATIVE
Christopher Gibbons, Boston, Massachusetts, USA

CHARCOT-MARIE-TOOTH AND RELATED NEUROPATHIES CONSORTIUM REPRESENTATIVE
Davide Pareyson, Milan, Italy

JPNS EDITOR
David Cornblath, Baltimore, Maryland, USA

SCIENTIFIC PROGRAM COMMITTEE
Robert Baloh - Co-Chair, Los Angeles, California, USA
Carla Taveggia - Co-Chair, Milan, Italy
David Adams, Le Kremlin Bicetre, France
Alessandra Bolino, Milan, Italy
Chiara Briani, Padova, Italy
David Cornblath, Baltimore, Maryland, USA
Christopher Gibbons, Baltimore, Maryland, USA
Satoshi Kuwabara, Chiba, Japan
Richard Lewis, Los Angeles, California, USA
Ingemar Merkies, Rotterdam, Netherlands
Davide Pareyson, Milan, Italy
Michael Polydefkis - MHS Secretary/Treasurer, Baltimore, Maryland, USA
Mary M. Reilly - Past President, London, United Kingdom
Steven S. Scherer - President, Philadelphia, Pennsylvania, USA
Kasim Sheikh, Houston, Texas, USA
John Svaren, Madison, Wisconsin, USA
Pieter Van Doorn - President-Elect, Rotterdam, Netherlands
Brian Wainger, Cambridge, Massachusetts, USA
**Why Join:** We are an international organization of physicians and scientists working together to develop and provide the best treatments for people who have peripheral nerve diseases. This goal is realized by cooperation supporting research, training scientists, physicians and other healthcare professionals, setting standards of care, creating new treatments, and facilitating clinical trials.

**Networking.** Becoming a member of the PNS means collaborating with prominent global scientists, physicians and other healthcare professionals.

**Education.** PNS provides members with direct access to the JPNS, discounted Annual Meeting registration fees, guidelines, the latest updates on what’s happening in the field, and other resources to aid in the education of members.

**What to expect from your new membership?**
- Access to Member Directory
- Journal of the Peripheral Nervous System (JPNS)
- Voting Rights
- Patient Information
- Career Planning
- Volunteer Opportunities
- Discounted Annual Meeting Rates
- PNS Members may join SIG groups upon request.

**Visit [www.pnsociety.com](http://www.pnsociety.com) to Join Today!**
The Peripheral Nerve Society was founded in 1994 from two groups of academic investigators, Peripheral Nerve Study Group and Peripheral Neuropathy Association of America, interested in the basic biology and function of the peripheral nervous system and its application to both. Their invite-only biennial meetings involved 80-125 attendees in cloistered settings organized by a shoestring and driven by local initiative. From this, we have grown remarkably. We now have an Annual Meeting of over 600 people including meetings within the meeting for the special interest groups in inflammatory, diabetic and hereditary neuropathy. With this substantial growth and the success of JPNS, the Journal of the Peripheral Nervous System, the Society continues to flourish.

The Peripheral Nerve Society provides Annual Meetings, Teaching Courses, Guidelines, and other resources to aid in the education of members. Becoming a member of PNS means collaborating with prominent global professionals in the field to develop and provide the best treatments for people with peripheral nerve diseases and setting standards of care within the field. Please participate in our future by joining the PNS, volunteering for a project aligned with your interests and sending your ideas for the future to the Executive Office, or Board member.

CONTACT US
info@PNSociety.com | www.pnsociety.com | +1-952-545-6284
PAST MEETINGS

PAST MEETINGS OF THE PNS
2017  Sitges-Barcelona, Spain
2015  Quebec City, Canada
2013  Saint-Malo, France
2011  Potomac, Maryland
2009  Würzburg, Germany
2007  Snowbird, Utah
2005  Tuscany, Italy
2003  Banff, Canada
2001  Tyrol, Austria
1999  La Jolla, California
1997  Cambridge, England
1995  Antalya, Turkey
1994  Saint Paul, Minnesota

PAST MEETINGS OF THE PNSG
1993  Boppard, Germany
1991  Arden House, New York
1989  Padua, Italy
1987  Lake Couchiching, Ontario, Canada
1985  Mürren, Switzerland
1983  Fontevraud, France
1981  Shakertown, Kentucky
1979  Wye College, Kent, England
1977  Airlie House, Virginia
1975  Rochester, Minnesota
1974  Carville, Louisiana

PAST MEETINGS OF THE PNAA AND PNA
1992  Rapallo, Italy
1990  Oxford, England
1989  Maui, Hawaii
1988  Halifax, Nova Scotia, Canada
1986  Hilton Head Island, South Carolina
1985  Keystone, Colorado
1984  Keystone, Colorado
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>2</td>
</tr>
<tr>
<td>Leadership</td>
<td>3</td>
</tr>
<tr>
<td>Membership Information</td>
<td>4</td>
</tr>
<tr>
<td>About the Society</td>
<td>5</td>
</tr>
<tr>
<td>Past Meetings</td>
<td>6</td>
</tr>
<tr>
<td>Program at a Glance</td>
<td>8</td>
</tr>
<tr>
<td>Hotel Floor Plan</td>
<td>9</td>
</tr>
<tr>
<td>General Information</td>
<td>10</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>12</td>
</tr>
<tr>
<td>Exhibitor Directory</td>
<td>37</td>
</tr>
</tbody>
</table>

## PROGRAM

### SATURDAY
- Education Course .................................. 15
- Welcome Reception ................................ 16

### SUNDAY
- Plenary Session: Richard Bunge Lecture .......... 17
- Platform Session I ................................ 17
- Plenary Session: Peter J Dyck Lecture .......... 18
- Oral Poster Session I ............................. 18
- Poster Session I ................................ 19
- Parallel Session: INC .............................. 19
- Parallel Session: CMTR ............................ 20
- Parallel Session: DIABETES/PAIN .................. 22
- ACKEA Pharmaceuticals Symposium .................. 23
- CSL Behring Symposium ................................ 23
- Junior Reception ................................ 23

### MONDAY
- Plenary Session: Arthur K Asbury Lecture ........ 24
- Platform Session II ................................. 24
- Plenary Session: PK Thomas Lecture ............... 25
- Oral Poster Session II ............................. 25
- PNS General Meeting ................................ 26
- Poster Session II ................................ 26
- Parallel Session: INC .............................. 26
- Parallel Session: CMTR ............................ 27
- Parallel Session: DIABETES/PAIN .................. 28
- Alnylam Pharmaceuticals Symposium ............... 30
- Grifols Symposium ................................ 30
- All Member Reception ................................ 30

### TUESDAY
- Plenary Session: Jack Griffin Lecture .......... 31
- Platform Session III ............................... 31
- Plenary Session: Pembroke Lecture ............... 32
- Oral Poster Session III ............................ 32
- Poster Session III ................................ 33
- Clinical Trials Updates ............................ 33
- Closing Keynote: Arthur Burghes ................. 34
- Awards & Prizes ................................... 34
- Closing Reception ................................ 34

### WEDNESDAY
- Special Interest Group (SIG): Toxic Neuropathy . . . 35
### PROGRAM AT A GLANCE

#### SATURDAY 21 JULY 2018
- **8.00-12.00** Individual Meeting: Inherited Neuropathy Consortium (HOMELAND)
- **9.00-18.00** Education Course (MARYLAND BALLROOM ABCD)
- **18.30-21.00** Welcome Reception (MARYLAND SCIENCE CENTER INNER HARBOR)

#### SUNDAY 22 JULY 2018
- **7.30-8.30** Light Breakfast & Poster Viewing (BALTIMORE BALLROOM A&B)
- **8.30-9.00** Plenary Session: Richard Bunge Lecture (MARYLAND BALLROOM A-D)
- **9.00-10.30** Platform Session I (MARYLAND BALLROOM A-D)
- **10.30-11.00** Coffee Break (MARYLAND FOYER)
- **11.00-11.30** Plenary Session: Peter J Dyck Lecture (MARYLAND BALLROOM A-D)
- **11.30-12.30** Oral Poster Session I (MARYLAND BALLROOM A-D)
- **12.30-13.00** Lunch & Poster Viewing (BALTIMORE BALLROOM A&B)
- **13.00-14.00** Individual Meeting: IMAGiNe Study (MARYLAND BALLROOM EF)
- **14.00-15.00** Plenary Session: Mark Johnson Lecture (MARYLAND BALLROOM A-D)
- **15.00-16.00** Poster Session II (BALTIMORE BALLROOM A&B)
- **16.00-16.30** Coffee Break (MARYLAND FOYER)
- **16.30-17.30** Sponsored Symposia
  - AKCEA Symposium (MARYLAND BALLROOM E&F)
  - Grifols Symposium (MARYLAND BALLROOM A-D)
- **18.00-20.00** Junior Reception (MARYLAND FOYER)

#### MONDAY 23 JULY 2018
- **7.30-8.30** Light Breakfast & Poster Viewing (BALTIMORE BALLROOM A&B)
- **8.30-9.00** Plenary Session: Arthur K Asbury Lecture (MARYLAND BALLROOM A-D)
- **9.00-10.30** Platform Session II (MARYLAND BALLROOM A-D)
- **10.30-11.00** Coffee Break (MARYLAND FOYER)
- **11.00-11.30** Plenary Session: Pembroke Lecture (CELL BIOLOGY)
  - Cell Biology (MARYLAND BALLROOM A-D)
- **11.30-12.30** Oral Poster Session II (MARYLAND BALLROOM A-D)
- **12.30 - 13.00** Lunch & Poster Viewing (BALTIMORE BALLROOM A&B)
- **13.00-14.00** Poster Session III (BALTIMORE BALLROOM A&B)
- **14.00-16.00** Clinical Trials Updates and Late Breaking Abstract (MARYLAND BALLROOM A-D)
- **16.00-16.30** Coffee Break (MARYLAND FOYER)
- **16.30-17.30** Closing Keynote
  - Arthur Burghes (MARYLAND BALLROOM A-D)
- **17.30-18.00** Awards & Prizes (MARYLAND BALLROOM A-D)

#### TUESDAY 24 JULY 2018
- **7.30-8.30** Light Breakfast & Poster Viewing (BALTIMORE BALLROOM A&B)
- **8.30-9.00** Plenary Session: Jack Griffin Lecture (MARYLAND BALLROOM A-D)
- **9.00-10.30** Platform Session III (MARYLAND BALLROOM A-D)
- **10.30-11.00** Coffee Break (MARYLAND FOYER)
- **11.00-11.30** Plenary Session: Pembroke Lecture (CELL BIOLOGY)
  - Cell Biology (MARYLAND BALLROOM A-D)
- **11.30-12.30** Oral Poster Session III (MARYLAND BALLROOM A-D)
- **12.30 - 13.00** Lunch & Poster Viewing (BALTIMORE BALLROOM A&B)
- **13.00-14.00** Poster Session III (BALTIMORE BALLROOM A&B)
- **14.00-16.00** Clinical Trials Updates and Late Breaking Abstract (MARYLAND BALLROOM A-D)
- **16.00-16.30** Coffee Break (MARYLAND FOYER)
- **16.30-17.30** Closing Keynote
  - Arthur Burghes (MARYLAND BALLROOM A-D)
- **17.30-18.00** Awards & Prizes (MARYLAND BALLROOM A-D)

#### WEDNESDAY 25 JULY 2018
- **9.00-11.00** Special Interest Group (SIG): Toxic Neuropathy (MARYLAND BALLROOM EF)
GENERAL INFORMATION

REGISTRATION / HELP DESK HOURS
Friday, 20 July 17.30 – 19.30
Saturday, 21 July 7.30 – 18.00
Sunday, 22 July 7.30 – 18.00
Monday, 23 July 7.30 – 18.00
Tuesday, 24 July 7.30 – 18.00

REGISTRATION FEES
Registration fees include:
• Access to all conference sessions
• Breakfast, coffee breaks, and lunch
• Welcome Reception at the Maryland Science Center
• Junior Reception (all are welcome)
• All Member Reception
• Closing Session at the Camden Yards Baseball Field

BADGE
All conference participants are required to wear their name badge at all conference functions.

CERTIFICATE OF ATTENDANCE
Your certificate may be downloaded from the PNS website after the meeting.

WIFI INSTRUCTIONS
Complimentary WIFI is available in the meeting space.
Network: PNS2018
Password: pns2018

MOBILE APP INSTRUCTIONS
(use this to participate with the audience response system)
Navigate the event like a pro with the PNS 2018 Annual Meeting mobile app, powered by Core-apps.

With the PNS 2018 Annual Meeting app, you can:
• Stay organized with up-to-the-minute speaker, exhibitor and event information
• Receive important real-time communications from PNS
• Build a personalized schedule and bookmark exhibitors
• Take notes and download event handouts and presentations
• Find attendees and connect with your colleagues through Friends
• Stay in-the-know and join in on social media with #PNS2018
• Share your event photos and experience with the Photo Gallery
• And much, much more!

DOWNLOADING THE APP IS EASY!
While on your smartphone, point your mobile browser to http://app.core-apps.com/pnsm2018 to be directed to the proper download version for your device.
EXHIBITION
Please be sure to visit the exhibits located in the foyer at the breaks.

LIABILITY & INSURANCE
The organizers accept no responsibility for any injury or damage involving persons and property during the 2018 PNS Meeting.

POSTER SESSIONS

POSTER SESSION I:  Sunday 22 July  
Room: Baltimore Ballroom A&B  
Mandatory Stand by Time: 13.00-14.00

POSTER SESSION II:  Monday 23 July  
Room: Baltimore Ballroom A&B  
Mandatory Stand by Time: 13.00-14.00

POSTER SESSION III: Tuesday 24 July  
Room: Baltimore Ballroom A&B  
Mandatory Stand by Time: 13.00-14.00
ACKNOWLEDGMENTS

We thank the generosity of our sponsors. This program would not be possible without their support.

YEAR ROUND PARTNERS

Alnylam Pharmaceuticals
CSL Behring Biotherapies for Life®
Grifols

PLATINUM AND JUNIOR RECEPTION SPONSOR

AKCEA Therapeutics

SILVER SPONSORS

Biogen
Kedrion Biopharma
Octapharma

BRONZE SPONSORS

Acceleron
Pharnext

Please reference page 37 for the exhibitor directory.
ACKNOWLEDGMENTS

GENERAL SPONSORS

**TERUMO BCT**
**disarm THERAPEUTICS**
**BÜHLMANN**

**VERTEX**
**Shire**

**MAYO CLINIC**
Mayo Medical Laboratories

**INVITAE**

PATIENT ADVOCACY GROUPS (PAGS)

**CMTA**
Charcot-Marie-Tooth Association

**GBS | CIDP**
Foundation International

**Charcot-Marie-Tooth**
UK

**HEREDITARY NEUROPATHY FOUNDATION**

**EUROPEAN CMT FEDERATION**

**the FOUNDATION for PERIPHERAL NEUROPATHY®**
DEDICATED to REVERSING the IRREVERSIBLE

**AMYLOIDOSIS SUPPORT GROUPS**
*You Are Not Alone*
www.amyloidosisupport.org

**CMTFrance**

**AFANP**
07.30-18.00  Registration / Help Desk Open (MARYLAND FOYER)

8.00-12.00  Individual Meeting: Inherited Neuropathy Consortium (HOMELAND)
Hosted by: Michael Shy

09.00-18.00  Education Course (MARYLAND BALLROOM ABCD)
Chairs: Alex Rossor and Alessandra Bolino

09.00-09.45  An Overview of Peripheral Nerve Anatomy and Pathology
Steven Scherer

09.45-10.30  Disease Mechanisms in the Inherited Neuropathies
Vincent Timmerman

10.30-11.00  Coffee Break (MARYLAND FOYER)

Education Course Continued
Chairs: Michelle Mauerman and Ruth Huizinga

11.00-11.45  New Antibodies and Mechanisms in Immune Mediated Neuropathy
Claudia Sommer

11.45-12.30  How I Treat Paraproteinaemic Neuropathies
Michelle Mauermann

12.30-14.00  Lunch (MARYLAND FOYER)

Education Course Continued
Chairs: Josh Burns and Davide Pareyson

14.00-14.40  Genetic Therapies in CMT and Related Disorders, How They Work and Clinical Applications
John Svaren

14.40-15.20  The Journey from Preclinical to Clinical Trial: Lessons Learnt
Davide Pareyson

15.20-16.00  What Makes a Good Outcome Measure and How to Design One
Josh Burns

16.00-16.30  Coffee Break (MARYLAND FOYER)
Education Course Continued  
Chairs: Eduardo Nobile-Orazio and Pedro Tomaselli

16.30-18.00  **Case Presentation Competition**  
(Complete abstract details may be found in the abstract supplement)

16.30-16.45  Mononeuritis multiplex secondary to Lyme Neuroborreliosis  
_Chinar Osman, Wessex Neurological Centre_

16.45-17.00  Early onset neuropathy with episodes of worsening and brown urine: Mitochondrial trifunctional protein (MTP) deficiency  
_Vanessa Marques, School of Medicine of Ribeirão Preto - University of São Paulo_

17.00-17.15  Transthyretin Val107 mutation mimicking CIDP  
_Francisco de Assis Gondim, Universidade Federal do Ceará_

17.15-17.30  Two cases of CIDP after Zika virus infection  
_Sonja Leonhard, Department of Neurology, Erasmus Medical Centre Rotterdam, Netherlands_

17.30-17.45  The intolerable endotracheal tube, _Ludwig Gutmann, University of Iowa_

17.45-18.00  PNS Masters Education Course - Milan, Italy  
_Giuseppe Lauria_

18.30-21.00  **Welcome Reception**  (MARYLAND SCIENCE CENTER INNER HARBOR)  
The 2018 PNS Welcome Reception will kick off at the Maryland Science Center. Please join us in the inner harbor directly across from the hotel for amazing views, scientific activities, appetizers and a hosted bar. Directionals will be located outside of the hotel to help you find your way.

Maryland Science Center is located at 601 Light St, Baltimore, MD 21230
07.30-18.00  Registration / Help Desk Open  (MARYLAND FOYER)
07.30-08.30  Light Breakfast & Poster Viewing  (BALTIMORE BALLROOM AB)
08.30-09.00  Plenary Session: Richard Bunge Lecture  (MARYLAND BALLROOM ABCD)
              Introduction by Ludo Van Den Bosch

Autophagy Dynamics in Neuronal Homeostasis and Neurodegeneration
Erika Holzbaur, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

09.00-10.30  Platform Session I  (MARYLAND BALLROOM ABCD)
              Chairs: Haesun Kim and Mario Saporta
              (Complete abstract detail may be found in the abstract supplement)

09.00-09.15  Deacetylation E3-Ubiquitin Protein Ligase by Sirtuin 1 Over Expression Reverses T2D Peripheral Neuropathy, Krish Chandrasekaran, University of Maryland School of Medicine

09.15-09.30  Activation of the ER Stress Transcriptions Factor XBP1 Modulates Disease Severity in MT1B Mice, Maurizio D’Antonio, Division of Genetics and Cell Biology, San Raffaele Scientific Institute

09.30-09.45  CRISPR/Cas9 mediated PMP22 downregulation improves the phenotype in a rodent model of CMT1A, Ji-Su Lee, Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Korea

09.45-10.00  Insights into Bortezomib-Induced Neurotoxicity Using Proteomics in Human Pluripotent Stem Cell-Derived Sensory Neurons, Sybil Hrstka, Mayo Clinic

10.00-10.15  Restoring Mitofusin Balance in the Nervous System to Prevent Axonal Degeneration from Mutant MFN2, Yueqin Zhou, Center of Neural Science and Medicine, Cedars-Sinai Medical Center

10.30-11.00  Coffee Break  (MARYLAND FOYER)
11.00-11.30  **Plenary Session: Peter J Dyck Lecture** (MARYLAND BALLROOM ABCD)

Introduction by Paul Fernyhough

HCN2 ion channel activity in peripheral nociceptive nerve fibres drives inflammatory and neuropathic pain

Peter McNaughton, Kings College London, London, United Kingdom

11.30-12.30  **Oral Poster Session I** (MARYLAND BALLROOM ABCD)

Chairs: Daniela Menichella and Maurizio D’Antonio

(Complete abstract details may be found in the abstract supplement)

11.30-11.35  A kinase inhibitor improves neurofilament distribution in CMT2E human motor neuron axons, Mario Saporta, University of Miami, Florida

11.35-11.40  Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial, Senda Ajroud-Driss, Northwestern University Feinberg School of Medicine

11.40-11.45  Mitochondria–Lysosome Contacts Regulate Mitochondrial Dynamics via GTP Hydrolysis of Rab7 Linked to Charcot-Marie-Tooth 2B, Yvette Wong, Northwestern University Feinberg School of Medicine

11.45-11.50  CMT2, CRISPR and Stem Cells: Disease Mechanism and Genome Surgery, Bruce Conklin, Gladstone Institutes, UCSF, Innovative Genomics Institute

11.50-11.55  Deletion of SARM1 has a Protective Effect for High-fat Diet-induced Peripheral Neuropathy and Glucose Intolerance, Jun-Soon Kim, Johns Hopkins School of Medicine

11.55-12.00  Specific Contribution of Distinct Dorsal Root Ganglion Neuron Subtypes To Painful Diabetic Neuropathy, Nirupa Jayaraj, Northwestern University

12.00-12.05  The Construct Validity and Diagnostic Capability of Patient and Clinician Reported Measures of CIPN, Noah Kolb, University of Vermont

12.05-12.10  Molecular signatures of microangiopathy in nerve pathology of diabetic neuropathy, Sung-Tsang Hsieh, National Taiwan University Hospital

12.10-12.15  AAV Targeting of Peripheral Nervous System Dysfunction in Giant Axonal Neuropathy, Rachel Bailey, University of North Carolina at Chapel Hill
12.15-12.20  New Role of Sirt2 in Alleviating Cisplatin Induced Peripheral Neuropathy Pain, **Manchao Zhang**, *Department of Radiation Oncology, The University of Arkansas for Medical Sciences*

12.30-13.00  Lunch & Poster Viewing *(BALTIMORE BALLROOM AB)*

12.30-13.30  **Individual Meeting: IMAGiNE Study** *(MARYLAND BALLROOM EF)*  
Hosted by: **Ingemar Merkies**

13.00-14.00  **Poster Session I** *(BALTIMORE BALLROOM AB)*  
All presenters are required to stand by posters from 13.00 - 14.00.

14.00-18.00  **Special Interest Group (SIG) Parallel Sessions**

14.00-18.00  **Inflammatory Neuropathy Consortium (INC) (MARYLAND BALLROOM ABCD)**

14.00-14.30  INC Business and Reviews of New and Ongoing Projects  
Welcome and Introduction: **Richard Lewis**, *INC Chair*

14.00-14.10  Update on IGOS  
**Bart Jacobs**

14.10-14.30  Vasculitic neuropathy - registry and RODS scale development  
**Robert Hadden** and **Mike Collins**

14.30-15.00  Invited Talk: Experience with Diagnosis and Treatment of POEMS syndrome  
**Satoshi Kuwabara**  
Chair: **Chiara Briani**

15.00-16.00  **Oral Abstracts**  
Chairs: **Carina Bunschoten** and **Janev Fehmi**  
(Complete abstract details may be found in the abstract supplement)

15.00-15.10  Nerve Ultrasound for the Identification of Treatment-responsive Chronic Neuropathies without Nerve Conduction Abnormalities, **Stephan Goedee**, *Brain Center Rudolf Magnus, UMC Utrecht*

15.10-15.20  The safety and efficacy of thalidomide treatment prior to autologous stem-cell transplantation in POEMS syndrome, **Sonoko Misawa**, *Chiba University Graduate School of Medicine*

15.20-15.30  Intravenous immunoglobulin for mild Guillain-Barré syndrome: an international prospective observational study, **Joyce Roodbol**, *Erasmus MC*

15.30-15.40  Varied Phenotype and Treatment Responsiveness of Immune Checkpoint Inhibitor Associated Neuropathies: Report of 14 Patients, **Divyanshu Dubey**, *Brigham and Women’s Hospital and Massachusetts General Hospital, and Mayo Clinic*
PROGRAM – SUNDAY 22 JULY 2018

15.40-15.50 Innate Sensing of Viruses in the Guillain-Barré Syndrome, Ruth Huizinga, Erasmus MC, University Medical Centre

16.00-16.30 Coffee Break (MARYLAND FOYER)

16.30-17.00 Debates: The Next Best Clinical Trial in CIDP: B-Cell or T-Cell Immunomodulating Therapy? Bernd Kieseier and Mazen Dimachkie
Introduction by Luis Querol

17.00-17.30 Mechanisms of IVIG and SCiG Effectiveness in Immune Neuropathies Mel Berger
Chair: Thomas Harbo

17.30-18.00 Oral Abstracts
Chair: Judith Spies
(Complete abstract details may be found in the abstract supplement)

17.30-17.40 Comparison of Guillain-Barre Syndrome Between the Epidemic and Post-Epidemic Phases of Zika Virus in Colombia, Laura Munoz, Johns Hopkins Hospital

17.40-17.50 Virus discovery in chronic inflammatory demyelinating polynyeuropathy, Gwen van lieverloo, Academic Medical Center, Department of Neurology

17.50-18.00 Anti-MAG neuropathy: role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels, Nidhi Garg, Brain and Mind Centre, Sydney Medical School, The University of Sydney, NSW, Australia

14.00-18.00 ➤ Charcot-Marie-Tooth & Related Neuropathies Consortium (CMTR)
(MARYLAND BALLROOM ABCD)

14.00-14.30 Beyond Mendelian Genomics: The Expanding Concepts of Heredity In CMT Stephan Züchner
Chair: Steven Scherer

14.30-16.00 Oral Platform Presentations
Chairs: Manisha Juneja and Stefano Previtali
(Complete abstract information can be found in the abstract supplement)

14.30-14.45 Human Induced Pluripotent Stem Cell Differentiation towards a Schwann Cell Lineage Robert Prior, KU Leuven - Department of Neurosciences. VIB - Center for Brain and Disease Research

14.45-15.00 A Kinase inhibitor improves neurofilament distribution in CMT2E human motor neuron axons, Mario Saporta, University of Miami, Florida
15.00-15.15  In Vivo Translational Profiling of Motor Neurons in Mouse Models of Charcot-Marie-Tooth Type2D, Emily Spaulding, The Jackson Laboratory

15.15-15.30  Predictive modeling reveals threonyl-tRNA synthetase (TARS) as a candidate gene for human axonal peripheral neuropathy, Rebecca Meyer, University of Michigan

15.30-15.45  Mutations in HSPB1 impair its mitochondrial role, Elias Adriaenssens, Peripheral Neuropathy Research Group, Institute Born Bunge, University of Antwerp

15.45-16.00  Unravelling Mechanisms of Axonal Loss in Late-onset Genetic Neuropathies, Chiara Pisciotta, IRCCS Foundation, “C. Besta” Neurological Institute

16.00-16.30  Coffee Break (MARYLAND FOYER)

16.30-17.00  Structural Variation Causing Inherited Neuropathies: A Paradigm for Genomic Organisation, Chromatin Interactions and Gene Dysregulation, Marina Kennerson, ANZAC Research Institute, Australia
Chair: Charlotte Sumner

17.00-17.45  Oral Platform Presentations
Chairs: Jonathan Baets & Chiara Pisciotta
(Complete abstract information can be found in the abstract supplement)

17.00-17.15  Mutations in Cell Adhesion Molecules Belonging to the CADM Family Cause Charcot-Marie-Tooth Disease, Adriana Rebelo, University of Miami, Florida

17.15-17.30  Expanding the phenotype of neuromuscular disorders: NGS reveals new genes responsible for recessive motor neuropathies, Stefano Previtali, IRCCS San Raffaele Scientific Institute

17.30-17.45  Alpha-spectrin haploinsufficiency through SPTAN1 nonsense mutations causes a spectrum of juvenile onset hereditary motor neuropathies, Danique Beijer, Neurogenetics Group, CMN-VIB, University of Antwerp

17.45-18.00  Oral Poster Mini-Session
Chairs: Jonathan Baets & Chiara Pisciotta

17.45-17.52  Autosomal recessive Charcot Marie Tooth disease: Clinical, Electrophysiology and genetic spectrum in a Tunisian series, Emna Ellouz, Gabes Hospital

17.53-18.00  Clinical and Genetic Spectra of Charcot-Marie-Tooth disease in Chinese Han Patients, Huang Xusheng, Department of Neurology, Chinese PLA General Hospital
PROGRAM – SUNDAY 22 JULY 2018

14.00-18.00  Diabetic Neuropathy Consortium (WATERTABLE BALLROOM)

14.00-14.15  Introduction to the Diabetic Neuropathy Consortium
Christopher Gibbons

14.15-16.00  Keystone Target Talks
Chairs: Marta Campagnolo and James Russell

14.15-14.35  Obesity Mechanisms as a Targetable Endpoint in Diabetic Neuropathy
Doug Wright

14.35-14.55  Keystone Target Talk - (Lipids and Neuropathy)
Mark Yorek

14.55-15.15  Nox5 as a therapeutic Target
Stephanie Eid

15.15-15.35  Stem Cells as a Potential Treatment in Diabetic Neuropathy
Tatsuo Nokamura

15.35-16.00  Muscarinic Receptors as a Targetable Endpoint in Diabetic Neuropathy
Paul Fernyhough

16.00-16.30  Coffee Break (MARYLAND FOYER)

16.30-17.00  Insulin Signaling Pathways as a Potential Therapeutic Target in DPN
Doug Zochodne

17.00-17.30  Oral Platform Presentations
Chairs: Cheng-Ying Ho and Doug Wright
(Complete abstract information can be found in the abstract supplement)

17.00-17.15  Metabolic Syndrome Components and Neurologic Outcomes in a
Bariatric Surgery Population, Brian Callaghan, University of Michigan

17.15-17.30  Caloric Restriction in BKS Db/db Mice does not Ameliorate Diabetic
Peripheral Neuropathy, Phillipe O’Brien, University of Michigan

17.30-18.00  Oral Poster Presentations
Chairs: Stephanie Eid and Paul Fernyhough
(Complete abstract information can be found in the abstract supplement)

17.30-17.35  Alterations in DRG Calcium Signaling and Mitochondrial Homeostasis
in Painful Diabetic Neuropathy, Sandra Hackelberg, Northwestern University
17.35-17.40 Uncovering an Important Role for Monocarboxylate Transporter MCT1 in Diabetic Neuropathy, Mithilesh Jha, Department of Neurology, Johns Hopkins University School of Medicine

17.40-17.45 IGF-1 Signals Through Different Isoforms of AMPK to Control Mitochondrial Function in Adult Sensory Neurons, Darrell Smith, St. Boniface Research Centre

17.45-17.50 Induced expression of keratinocyte-derived BDNF by SIRT1 activation alleviates diabetic neuropathy, Cheng-Ying Ho, University of Maryland School of Medicine

18.00-19.00 ACKEA Pharmaceuticals Symposium (MARYLAND EF)
Hereditary Transthyretin (hATTR) Amyloidosis: An Underrecognized Cause of Peripheral Sensorimotor Neuropathy
Speakers: Thomas Brannagan and Michelle Mauermann
Chair: Jim Dyck

18.00-19.00 CSL Behring Symposium (MARYLAND ABCD)
18.00-18.05 Welcome and Introduction
Richard Lewis

18.05-18.20 Subcutaneous Immunoglobulin in CIDP: The Evidence
Thomas Harbo

18.20-18.35 Practical Aspects in Subcutaneous Immunoglobulin Administration
Melody Bullock

18.35-18.50 Objective Measures You Should Use to Monitor CIDP and Treatment Response
Jeffrey Allen

18.50-19.00 Q&A and Closing Remarks
Richard Lewis

19.00-20.00 Junior Reception (MARYLAND FOYER)
All are encouraged to attend.
Sponsored by:
**PROGRAM – MONDAY 23 JULY 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30-18.00</td>
<td>Registration / Help Desk Open <strong>(MARYLAND FOYER)</strong></td>
<td></td>
</tr>
<tr>
<td>07.30-08.30</td>
<td>Light Breakfast &amp; Poster Viewing <strong>(BALTIMORE BALLROOM AB)</strong></td>
<td></td>
</tr>
<tr>
<td>08.30-09.00</td>
<td><strong>Plenary Session: Arthur K Asbury Lecture</strong> <strong>(MARYLAND BALLROOM ABCD)</strong></td>
<td><strong>Introduction by</strong> Susumu Kusunoki</td>
</tr>
<tr>
<td></td>
<td>Shared B Cell - Mediated Immunopathology in CIDP, myasthenia gravis, and other IgG4 - Mediated Diseases <strong>Kevin O’Connor</strong>, Yale University, New Haven, CT, USA</td>
<td></td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Platform Session II</strong> <strong>(MARYLAND BALLROOM ABCD)</strong></td>
<td><strong>Chairs:</strong> Kleopas Kleopa and Ruth Huizinga</td>
</tr>
<tr>
<td></td>
<td><strong>(Complete abstract information can be found in the abstract supplement)</strong></td>
<td></td>
</tr>
<tr>
<td>09.00-09.15</td>
<td>Preliminary Phase 2 Results for ACE-083, Local Muscle Therapeutic, in Patients with CMT1 and CMTX, Florian Thomas, Hackensack University Medical Center and Seton Hall University</td>
<td></td>
</tr>
<tr>
<td>09.15-09.30</td>
<td>Allele-Specific RNA Interference: Precision Gene Therapy for Dominant Inherited Neuropathy, Robert Burgess, The Jackson Laboratory</td>
<td></td>
</tr>
<tr>
<td>09.30-09.45</td>
<td>Placebo Effect in The PATH Study of Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy, Richard Lewis, Department of Neurology, Cedars-Sinai Medical Center</td>
<td></td>
</tr>
<tr>
<td>09.45-10.00</td>
<td>Atypical CIDP: diagnostic criteria, progression and response to therapy. Data from the Italian CIDP Database, Pietro Doneddu, Humanitas Research Hospital</td>
<td></td>
</tr>
<tr>
<td>10.00-10.15</td>
<td>Altered actin dynamics contributes to severe myelination defects following Schwann cell-specific deletion of phosphatidylinositol 4-kinase-Illα, Alejandro Alvarez-Prats, National Institutes of Health (NIH/NICHD)</td>
<td></td>
</tr>
<tr>
<td>10.15-10.30</td>
<td>Regional Variation of Guillain-Barré Syndrome, Alexandra Doets, Erasmus University Medical Center</td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td>Coffee Break <strong>(MARYLAND FOYER)</strong></td>
<td></td>
</tr>
</tbody>
</table>
MONDAY PROGRAM – MONDAY 23 JULY 2018

11.00-11.30  **Plenary Session: PK Thomas Lecture** *(MARYLAND BALLROOM ABCD)*
Introduction by **Lucia Notterpek**

Phospholipid Metabolism and the Control of Schwann Cell Myelination
**Alessandra Bolino,** *San Raffaele Scientific Institute, Milan, Italy*

11.30-12.30  **Oral Poster Session II** *(MARYLAND BALLROOM ABCD)*
Chairs: **Claudia Sommer** and **Maureen Su**
(Complete abstract information can be found in the abstract supplement)

11.30-11.35  Mtmr2 loss impairs lysosome-associated intracellular signaling in Schwann cells: the impact on the myelin homeostasis, **Haesun Kim,** *Rutgers University*

11.35-11.40  Wnt Signaling in Schwann Cells Contributes to Peripheral Nerve Regeneration, **Benayahu Elbaz,** *The University of Chicago*

11.40-11.45  Mutations in Cell Adhesion Molecules Belonging to the CADM Family Cause Charcot-Marie-Tooth Disease, **Adriana Rebelo,** *University of Miami Miller School of Medicine*

11.45-11.50  The Importance of Genetic Screening of Voltage Gated Sodium Channels in Pure Small Fiber Neuropathy, **Amir Far,** *Maastricht University Medical Center*

11.50-11.55  CSF Sphingomyelin concentration: a myelin biomarker for acquired demyelinating neuropathies, **Lucilla Nobbio,** *University of Genoa*

11.55-12.00  Clinical course and outcome of Guillain-Barré syndrome in Bangladesh, **Badrul Islam,** *International Center for Diarrhoeal Disease Research, Bangladesh*

12.00-12.05  Immunoglobulin dosing in inflammatory neuropathy: An induction, maintenance and cessation algorithm, **Laura Compton,** *National Hospital for Neurology and Neurosurgery*

12.05-12.10  Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy, **Gwen van lieverloo,** *Academic Medical Center*

12.10-12.15  International Zika virus related Guillain-Barré Syndrome Outcome Study (IGOS-Zika): Update of a case-controlled study, **Sonja Leonhard,** *Department of Neurology, Erasmus Medical Centre*

12.15-12.20  Effectiveness of Limited plasma exchange (LPE) in Guillain-Barré syndrome (GBS), **Yan Lynn Aung,** *Yangon General Hospital*
**PROGRAM – MONDAY 23 JULY 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30-13.00</td>
<td><strong>PNS Annual General Meeting</strong> <em>(MARYLAND BALLROOM ABCD)</em></td>
</tr>
<tr>
<td></td>
<td>All are welcome to attend</td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch <em>(BALTIMORE BALLROOM AB)</em></td>
</tr>
<tr>
<td>13.00-14.00</td>
<td><strong>Poster Session II</strong> <em>(BALTIMORE BALLROOM AB)</em></td>
</tr>
<tr>
<td></td>
<td>All Presenters are required to stand by posters from 13.00-14.00</td>
</tr>
<tr>
<td>14.00-18.00</td>
<td><strong>Special Interest Group (SIG) Parallel Sessions</strong></td>
</tr>
<tr>
<td>14.00-18.00</td>
<td><strong>Inflammatory Neuropathy Consortium (INC)</strong> <em>(MARYLAND BALLROOM ABCD)</em></td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>INC Business and Reviews of New Ongoing Projects</td>
</tr>
<tr>
<td></td>
<td>Chair: Peter Van den Bergh, INC Vice-Chair</td>
</tr>
<tr>
<td>14.00-14.10</td>
<td>IMAGiNe Study</td>
</tr>
<tr>
<td></td>
<td>Ingemar Merkies</td>
</tr>
<tr>
<td>14.10-14.20</td>
<td>CIDP Databases</td>
</tr>
<tr>
<td></td>
<td>Filip Eftimov</td>
</tr>
<tr>
<td>14.20-14.30</td>
<td>Italian CIDP Database: What we Have Learned from the First 500 Patients</td>
</tr>
<tr>
<td></td>
<td>Eduardo Nobile-Orazio</td>
</tr>
<tr>
<td>14.30-15.00</td>
<td>Invited Talk: Paraneoplastioc Neuropathies</td>
</tr>
<tr>
<td></td>
<td>JC Antoine</td>
</tr>
<tr>
<td></td>
<td>Chair: Emilian Delmont</td>
</tr>
<tr>
<td>15.00-15.50</td>
<td><strong>Oral Platform Presentations</strong></td>
</tr>
<tr>
<td></td>
<td>Chairs: Islam Badrul and Joyce Roodbol</td>
</tr>
<tr>
<td></td>
<td><em>(Complete abstract information can be found in the abstract supplement)</em></td>
</tr>
<tr>
<td>15.00-15.10</td>
<td>Second IVIg course in Guillain-Barré syndrome with poor prognosis:</td>
</tr>
<tr>
<td></td>
<td>the non-randomized I-SID study, Christine Verboon, Erasmus MC</td>
</tr>
<tr>
<td>15.10-15.20</td>
<td>The 2016 Singapore ZIKV Outbreak did not cause a Surge in Guillain-</td>
</tr>
<tr>
<td></td>
<td>Barré Syndrome, Brandon C.J. Ng, Yong Loo Lin School of Medicine,</td>
</tr>
<tr>
<td></td>
<td>National University of Singapore, Singapore</td>
</tr>
<tr>
<td>15.20-15.30</td>
<td>The Natural History of POEMS Syndrome: practice review from the</td>
</tr>
<tr>
<td></td>
<td>largest UK single centre experience, Stephen Keddie, National</td>
</tr>
<tr>
<td></td>
<td>Hospital of Neurology and Neurosurgery</td>
</tr>
<tr>
<td>15.30-15.40</td>
<td>Prevalence and Associations of Peripheral Neuropathy at Disease-</td>
</tr>
<tr>
<td></td>
<td>Onset in ANCA-Associated Vasculitides: Data from DCVAS Study,</td>
</tr>
<tr>
<td></td>
<td>Michael Collins, Medical College of Wisconsin</td>
</tr>
<tr>
<td>15.40-15.50</td>
<td>Guillain-Barré Syndrome in Denmark—a Population Based Study of</td>
</tr>
<tr>
<td></td>
<td>Epidemiology and Clinical Characteristics, Helle Al-Hakem, Department</td>
</tr>
<tr>
<td></td>
<td>of Neurology, Aarhus University Hospital</td>
</tr>
</tbody>
</table>
16.00-16.30 Coffee Break (MARYLAND FOYER)

16.30-17.00 Debates: Perspectives on Electrodiagnostic Criteria for Guillain-Barre Syndrome
   Nortina Shahrizalia and Peter Van den Bergh
   Chair: Umapathi Thirugnanam

17.00-17.30 Invited Talk: Update on Multifocal Motor Neuropathy
   Ludo van der Pol
   Chair: Robert Hadden

17.30-18.00 Oral Platform Presentations
   Chair: Govind Chavada
   (Complete abstract information can be found in the abstract supplement)
   
   17.30-17.40 Axial Sensory Loss in Acquired Demyelinating Polyneuropathies, João Paulo Alves, Ribeirão Preto Medical School, University of São Paulo
   
   17.40-17.50 Clinical and electrodiagnostic findings in neuropathy with anti-Fibroblast Growth Factor Receptor 3 antibodies, Raghu Govindarajan
   
   17.50-18.00 A Three-year Nerve Ultrasound Longitudinal Study in 19 Patients with CIDP, Laura Fionda, Sant’Andrea Hospital, Sapienza University of Rome

14.00-18.00 ➤ Charcot-Marie-Tooth & Related Neuropathies Consortium
   (MARYLAND BALLROOM EF)
   
   14.00-14.30 PMP22 Antisense Oligonucleotides in Rodent Models of the Charcot-Marie-Tooth Disease Type 1A Duplication
   John Svaren
   Chair: Michael Shy

14.30-16.00 Oral Platform Session
   Chairs: Andoni Echaniz-Laguna and Kayla Cornett
   (Complete abstract information can be found in the abstract supplement)
   
   14.30-14.45 CMT2, CRISPR and Stem Cells: Disease Mechanism and Genome Surgery, Bruce Conklin, Gladstone Institutes
   
   14.45-15.00 Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease (CMT1A), Rene Goedkoop, PharmEx SA
   
   15.00-15.15 1st in Human IT Gene Transfer for GAN:Review of Safety,Immunology & Interim Analysis of Efficacy, Dimah Saade, NIH, NINDS, NNDCS
   
   15.15-15.30 Therapeutic effects of HDAC6 inhibitors in models of inherited and acquired neuropathies, Ludo Van Den Bosch, KU Leuven & VIB
   
   15.30-15.45 Development and validation of the CMT Infant Scale, Melissa Mandarakas, University of Sydney; Sydney Children’s Hospitals Network (Randwick and Westmead)
15.45-16.00  Serum biomarker discovery for Charcot-Marie-Tooth disease, Matthew Jennings, Newcastle University

16.00-16.30  Coffee Break (MARYLAND FOYER)

16.30-17.00  Overview of Lesson Learnt from Novel Therapies for Hereditary ATTR-neuropathy, Teresa Coelho
Chair: Mary Reilly

17.00-18.00  Platform Session
Chairs: Wilson Marques and Andrea Cortese
(Complete abstract information can be found in the abstract supplement)

17.00-17.15  Evolution of Amyloid Fibrils in Transthyretin Familial Amyloid Polyneuropathy: an Ultrastructural Study, Haruki Koike, Nagoya University Graduate School of Medicine

17.15-17.30  Development and Validation of the Transthyretin Familial Amyloid Polyneuropathy Score (TTR-FAP Score), Teresa Coelho, Unidade Corino de Andrade, Centro Hospitalar do Porto

17.30-17.45  Identifying the transition from TTR carrier to TTR neuropathy patient, Michael Polydefkis, Johns Hopkins Hospital

17.45-18.00  Familial Amyloid Polyneuropathy: Impact of Biopsies and Mutations on Diagnostic Considerations, Christopher Gibbons, Beth Israel Deaconess Medical Center, Harvard Medical School

14.00-18.00  ➤ Diabetic Neuropathy Consortium (WATERTABLE BALLROOM)

14.00-14.30  Moderated Panel Debate Neurophysiology endpoint talks (EMG, QST, Autonomic) 
Vera Bril, James Russell, Amanda Peltier
Chair: Eva Feldman

14.30-15.00  Moderated Panel Debate: Structural Endpoint Talks (CCM, Skin Biopsy, Sural Nerve Biopsy)
Rayaz Malik, Michael Polydefkis and Gordon Smith
Chair: James Russell

15.00-15.20  Perspective on Endpoints
Eva Feldman and Roy Freeman
Introduction by Rodica Pop-Busui

15.20-15.40  What’s New in DLRPN
Jim Dyck
Introduction by Rodica Pop-Busui
15.40-16.00  What’s New in TIND  
**Christopher Gibbons**  
Introduction by **Rodica Pop-Busui**

16.00-16.30  Coffee Break  *(MARYLAND FOYER)*

16.30-17.00  Diabetic Peripheral Neuropathy and the Opioid Crisis  
**Brian Callaghan**  
Introduction by **Lindsay Zilliox**

17.00-17.30  **Platform Session**  
(Complete abstract information can be found in the abstract supplement)

17.00-17.15  A Randomized, Blinded, Lifestyle Intervention Study Improves the Expiration:Inspiration Ration in Diabetic Neuropathy, **Lindsay Zilliox**, *University of Maryland School of Medicine*

17.15-17.30  Sensory Axons Inhibit Motor Axon Regeneration in vitro, **Thomas Brushart**, *Johns Hopkins*

17.30-18.00  **Oral Poster Session**  
Chairs: **Phillipe O’Brien** and **Amanda Peltier**  
(Complete abstract information can be found in the abstract supplement)

17.30-17.35  Expression of GAP-43 in Sensory Axon Terminals, **Xin Pan**, *Department of Neurology, Johns Hopkins School of Medicine*

17.35-17.40  Risk Of Developing Treatment-Induced Neuropathy In Diabetes; A Nested Case-control Study, **Jing Hang Randy Soh**, *Yong Loo Lin School of Medicine, National University Singapore*

17.40-17.45  An immortalized human DRG neuronal cell line to model diabetic and chemotherapy induced peripheral neuropathies, **Weiran Chen**, *Department of Neurology, The Johns Hopkins Medical School*

17.45-17.50  Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy: Design and Analysis Plan, **A. Gordon Smith**, *Virginia Commonwealth University*
PROGRAM – MONDAY 23 JULY 2018

Alnylam Pharmaceuticals Symposium (MARYLAND BALLROOM EF)
A History of hATTR Amyloidosis: Understanding the Disease and Evolution of Diagnostic Strategies
Chair: Michael Polydefkis
Michael Shy and Brian Drachman

GRIFOLS

Grifols Symposium (MARYLAND BALLROM ABCD)
Small Fiber Polyneuropathy and Autoimmunity: Preparing For Clinical Trials
Chair: Anne Louise Oaklander

18.00-18.05 SPIN Award ceremony

18.05-18.15 Overview of apparently autoimmune small fiber polyneuropathy, Anne Louise Oaklander (Boston, USA)

18.15-18.35 Intravenous immunoglobulin therapy for small fiber neuropathy: protocol and study update, Ingemar Merkies (Maastricht, The Netherlands)

18.35-18.55 Inflammatory markers in treatment induced neuropathy of diabetes: Protocol and study update, Christopher Gibbons (Boston, USA)

18.55-19.00 A double-blind, placebo controlled trial of IVIG in patients with small fiber neuropathy associated with autoantibodies to TS-HDS and FGFR3: protocol and study update, Christopher Gibbons (Boston, USA)

19.00-20.00 All Member Reception (MARYLAND FOYER)
All members are encouraged to attend the reception.
07.30-18.00 Registration / Help Desk Open (MARYLAND FOYER)

07.30-08.30 Light Breakfast & Poster Viewing (BALTIMORE BALLROOM AB)

08.30-09.00 Plenary Session: Jack Griffin Lecture (MARYLAND BALLROOM ABCD)
Introduction by Ahmet Hoke

The regulation of peripheral nerve repair by Schwann cells
David Parkinson, Plymouth University School of Medicine and Dentistry, Plymouth, United Kingdom

09.00-10.30 Platform Session III (MARYLAND BALLROOM ABCD)
Chairs: Jim Dyck and Brett Morrison
(Complete abstract information can be found in the abstract supplement)

09.00-09.15 Trapped in the epineurium: Early entry into endoneurium is restricted to neuritogenic T-cells in EAN, Anne Mausberg, University Hospital Essen, Department of Neurology

09.15-09.30 Impaired motor axon radial sorting and growth precede an early wave of degeneration in SMA, Lingling Kong, Johns Hopkins University

09.30-09.45 A promising new drug candidate for the treatment of anti-MAG neuropathy, Pascal Haenggi, Institute of Molecular Pharamcy, University of Basel

09.45-10.00 Two-Photon Imaging of Human Neuromuscular Junction Degradation After Traumatic Peripheral Nerve Injury, Ranjan Gupta, University of California, Irvine

10.00-10.15 Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases, Divyanshu Dubey, Mayo Clinic

10.15-10.30 A randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Eduardo Nobile-Orazio, IRCCS Istituto Clinico Humanitas, Milan University

10.30-11.00 Coffee Break (MARYLAND FOYER)
11.00-11.30  **Plenary Session: Pembroke Lecture** (MARYLAND BALLROOM ABCD)
Introduction by **Marina Kennerson**

Common cellular pathogenic themes for hereditary spastic paraplegias and neuropathies
**Craig Blackstone, NINDS Cell Biology Section, Bethesda, MD, USA**

11.30-12.30  **Oral Poster Session III** (MARYLAND BALLROOM ABCD)
Chairs: **Anthony Antonellis** and **Matilde Laura**
(Complete abstract information can be found in the abstract supplement)

11.30-11.35  PACSIN-1 released from injured axons may activate the Schwann Cell Repair Program after PNS injury, **Curtis Triebswetter, University of California, San Diego**

11.35-11.40  Molecular phenotyping of neurons derived from CMT2 patient-iPSC lines, **Manisha Juneja, University of Antwerp**

11.40-11.45  Focal Reduction of Monocarboxylate Transporter 1 (MCT1) in Macrophages Delays Peripheral Nerve Regeneration, **Brett Morrison, Johns Hopkins University**

11.45-11.50  Digit Wrinkle Scan©: from Normative Values to its Clinical Applicability in Small Fiber Neuropathy, **Isis Joosten, Maastricht University Medical Center**

11.50-11.55  Temporal variability of the binding specificity of IgM M-proteins in anti-MAG neuropathy, **Susumu Kusunoki, Kindai University Faculty of Medicine**

11.55-12.00  Ultrastructural Mechanisms of Macrophage-induced Demyelination in Chronic Inflammatory Demyelinating Polyneuropathy, **Haruki Koike, Nagoya University Graduate School of Medicine**

12.00-12.05  Clinical Heterogeneity of Paraproteinemic Polyneuropathies, **Aleksa Palibrk, Neurology Clinic, Clinical Centre of Serbia**

12.05-12.10  α7 nicotinic acetylcholine receptors (nAChRs) play an important role in chemotherapy-Induced Peripheral Neuropathy in mice, **M. Imad Damaj, Virginia Commonwealth University**

12.10-12.15  Schwann Cell-derived Desert Hedgehog Regulates the Endoneurial Fibroblast Phenotype in Peripheral Nerves via Gli1, **Brendan Zotter, NYU School of Medicine**

12.15-12.20  Practical Application of Subcutaneous Immunoglobulin For Maintenance Treatment In CIDP: The PATH Study, **Mazen Dimachkie, University of Kansas Medical Center**
PROGRAM – TUESDAY 24 JULY 2018

12.30-13.00 Lunch & Poster Viewing (BALTIMORE BALLROOM AB)

13.00-14.00 Poster Session III (BALTIMORE BALLROOM AB)
All Presenters to stand by posters from 13.00-14.00.

14.00-16.00 Clinical Trials Updates (MARYLAND BALLROOM ABCD)
Chairs: Mary Reilly & David Cornblath

14.00-14.10 Long-term Safety and Efficacy of Subcutaneous Immunoglobulin IgPro20 in CIDP: the PATH Extension Study
Orell Mielke

14.10-14.20 Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in CIDP: the PATH Study
Amgad Shebl

14.20-14.30 Clinical Characteristics of Patients with Active Disease: Can we Optimise Patient Selection for Trials
Mahima Kapoor

14.30-14.40 OPTIC Trial: Intravenous Immunoglobulin And Intravenous Methylprednisolone As Induction Treatment In CIDP (protocol)
Sander Bus

14.40-14.50 Pilot Screening Study of B Cell Depletion Therapy in CIDP
Mazen Dimachkie

14.50-15.00 Japanese eculizumab trial for Guillain-Barré syndrome (JET-GBS): The current status and perspective
Sonoko Misawa

15.00-15.10 Small volume plasma exchange for Guillain-Barré syndrome: a phase II safety and feasibility study
Badrul Islam

15.10-15.20 Second IVIg Course in Guillain-Barre syndrome patients with poor prognosis (SID-GBS trial)
Christa Walgaard

15.20-15.30 Patient Assisted Intervention for Neuropathy: Comparison of treatment in real life situations (PAIN-CONTRoLS)
Mamatha Pasnoor

15.30-15.40 Late Breaking Abstract: A Novel Recessive Pentanucleotide Repeat Expansion is a Frequent Cause of Late-onset Sensory Ataxic Neuropathy, Andrea Cortese, MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology
PROGRAM – TUESDAY 24 JULY 2018

16.00-16.30 Coffee Break (MARYLAND FOYER)

16.30-17.30 Closing Keynote Lecture (MARYLAND ABCD)
Introduction by Charlotte Sumner

Spinal Muscular Atrophy from Gene to Treatment
Arthur Burghes, The Ohio State University College of Medicine, Columbus, OH, USA

17.30-18.00 Awards & Prizes (MARYLAND ABCD)

18.30 Closing Reception at Camden Yards: Orioles vs Red Sox Baseball Game
Buses will depart from the main hotel entrance. Please make sure to bring your badge with you in order to get into the game.
09.00-11.00  SPECIAL INTEREST GROUP (SIG): Toxic Neuropathy (MARYLAND EF)
Hosted by Guido Cavaletti
Table 1  
**Akcea Therapeutics**  
www.akceatx.com  
info@akceatx.com  

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious and rare diseases. The name “Akcea” is derived from the Greek word for value and worth. Something that has “akcea” is not common, but precious and rare. Our name supports the value we are creating for the healthcare provider community, patients, and their families. We are driven by knowing that patients depend on us.

Table 2  
**CSL Behring**  
www.cslbehring.com  

CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ need using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions such as coagulation disorders, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.

Table 3  
**Alnylam Pharmaceuticals, Inc.**  
www.alnylam.com  
info@alnylam.com  

Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, and hepatic infectious diseases with unmet need. Alnylam’s investigational medicines include four late-stage product candidates, with one under regulatory review.

Table 4  
**GRIFOLS**  
www.grifols.com  
corporatecomms@grifols.com  

For more than 75 years, Grifols has worked to improve the health and well-being of people around the world. We are a global healthcare company that produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to deliver expert medical care.

Table 5  
**GBS/CIDP Foundation International**  
www.gbs-cidp.org  
lori.basiiego@gbs-cidp.org  

The GBS|CIDP Foundation International is the preeminent global nonprofit supporting individuals and their families affected by GBS, CIDP and related conditions. Through providing support, education, research and advocacy, the Foundation works for a future where no one suffers alone and everyone has access to the right diagnosis and the right treatment, right away.
The Charcot-Marie-Tooth Association is the world’s leading nonprofit organization dedicated to finding a cure for CMT. The CMTA’s Strategy to Accelerate Research (STAR) program brings top researchers together with pharmaceutical partners so that scientific breakthroughs are possible. The CMTA also offers community services including 70 branches, a camp and conferences.

Hereditary Neuropathy Foundation (HNF) is a non-profit 501(c)3 organization which mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth (CMT) and related INHERITED NEUROPATHIES, support patients and families with critical information to improve quality of life, and fund research that will lead to treatments and cures.

The Foundation for Peripheral Neuropathy (FPN) is a public charity foundation whose ultimate goal is to utilize every means and opportunity to dramatically improve the lives of those living with this painful and debilitating disorder. We achieve this mission by serving as the premier resource of information for patients, funding collaborative efforts of leading scientists, raising awareness, and accelerating a cure for peripheral neuropathy.

Amyloidosis Support Groups (ASG) is a 501 (C) 3 Non Profit founded in 2004. We run face to face support groups in more than 25 cities. We also have 8 Support Groups on Facebook and two online List-Servs. We published a 10 minute animated video and educational booklet, both of which can be found at www.amyloidaware.com.

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.
Table 16  Terumo BCT, Inc.  
www.terumobct.com  
NACOnferences@terumobct.com

**TERUMO BCT**

Unlocking the Potential of Blood

Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. We are committed to supporting clinicians and patients with education and research support for plasma exchange. Learn more about the immunomodulatory effects of plasma exchange in reducing disease mediators. In addition, learn about the convenience and safety of using plasma exchange in an outpatient setting using peripheral venous access. Contact us for more information: NACOnferences@terumobct.com

---

Table 17  Invitae  
www.invitae.com

**INVITAE**

Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices. Visit www.invitae.com.

---

Table 18  Mayo Medical Laboratories  
www.mayomedicallaboratories.com

**MAYO CLINIC**

Mayo Medical Laboratories (MML) is a global reference laboratory operating within Mayo Clinic’s Department of Laboratory Medicine and Pathology. MML supports neurology practices through comprehensive testing services with specialization in autoimmune, biochemical, and genetic testing. MML also offers muscle and nerve pathology services. Learn more at MayoMedicalLaboratories.com/neurology.

---

Table 19  Shire Medical  
www.shire.com/en

**Shire**

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.

---

Table 20  Biogen  
www.biogen.com

**Biogen**

---

Table 21  BÜHLMANN Laboratories AG  
www.buhlmannlabs.com  
sas@buhlmannlabs.com

**BÜHLMANN**

BUHLMANN Diagnostics Corp (BDC), the North American affiliate of BÜHLMANN Laboratories AG, offers a comprehensive neuroimmunology product line comprised of robust assays for simple, esoteric testing for important neuroimmune markers and it is supported by numerous clinical publications. Assays include BÜHLMANN GanglioCombi™ MAG ELISA, Anti-MAG Autoantibodies ELISA, and Anti-SGPG Autoantibodies ELISA.
**Table 22**

**Disarm Therapeutics**
www.disarmtx.com  
info@disarmtx.com

Disarm Therapeutics is creating breakthrough disease-modifying therapeutics that prevent axonal degeneration (AxD) for patients with neurological diseases. Our goal is to stop axon loss by inhibiting SARM1, the central driver of AxD in diseases of the central and peripheral nervous systems, including Multiple Sclerosis, ALS and peripheral neuropathies.

**Table 23**

**Vertex Pharmaceuticals**
www.vrtx.com

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Mass., Vertex’s headquarters is now located in Boston’s Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry’s top places to work, including being named to Science magazine’s Top Employers in the life sciences ranking for eight years in a row.

**Table 24**

**Acceleron Pharma, Inc.**
www.acceleronpharma.com  
info@acceleronpharma.com

Acceleron is a clinical-stage biopharmaceutical company dedicated to discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in TGF-beta biology and protein engineering generates innovative compounds that help regulate cellular growth and repair. Acceleron is advancing two distinct Myostatin+ agents, ACE-083 and ACE-2494, in neuromuscular diseases.

**Table 25**

**Alnylam Pharmaceuticals, Inc.**
www.alnylam.com  
info@alnylam.com

Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, and hepatic infectious diseases with unmet need. Alnylam’s investigational medicines include four late-stage product candidates, with one under regulatory review.

**Table 26**

**Terumo BCT, Inc.**
www.terumobct.com  
NAConferences@terumobct.com

Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. We are committed to supporting clinicians and patients with education and research support for plasma exchange. Learn more about the immunomodulatory effects of plasma exchange in reducing disease mediators. In addition, learn about the convenience and safety of using plasma exchange in an outpatient setting using peripheral venous access. Contact us for more information: NAConferences@terumobct.com.
Table 27  Octapharma  www.octapharma.com

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.

Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical care.

Table 28  Pharnext  www.pharnext.com/en/contact@pharnext.com

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that lack curative and/or disease-modifying treatments. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. PXT3003, Pharnext’s lead product, is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A, results are expected in the second half of 2018.

Table 29  Kedrion Biopharma  www.kedrion.us/r.mccune@kedrion.com

Kedrion Biopharma, an international biopharmaceutical company with corporate headquarters in Tuscany, Italy, specializes in the production of plasma-derived therapies for rare diseases and conditions such as hemophilia and primary immunodeficiency. Kedrion Biopharma’s US headquarters are in Fort Lee, New Jersey with a global presence in about 100 countries.
Hereditary Transthyretin (hATTR) Amyloidosis: An Underrecognized Cause of Peripheral Sensorimotor Neuropathy

OBJECTIVES

• To increase awareness of hATTR amyloidosis among neurologists
• To describe the multisystemic clinical presentation of hATTR amyloidosis and highlight diagnostic challenges
• To improve recognition of hATTR amyloidosis among neurologists

FACULTY

P. James B. Dyck, MD (Chair)
Mayo Clinic, Rochester, Minnesota

Thomas H. Brannagan III, MD
Columbia University, New York, New York

Michelle L. Mauermann, MD
Mayo Clinic, Rochester, Minnesota

OVERVIEW

Please join P. James B. Dyck, MD, and our expert faculty for a one-hour symposium that will provide an overview of hATTR amyloidosis, an underrecognized and often overlooked cause of peripheral sensorimotor neuropathy. The multisystemic manifestations and substantial overlap in clinical presentation of hATTR amyloidosis with other more common conditions make diagnosis challenging. In this symposium, the clinical features, variable presentation, and common challenges encountered with the diagnosis of hATTR amyloidosis will be reviewed. A retrospective look at a patient case study will be used throughout each presentation to exemplify key concepts that facilitate timely and accurate diagnosis, ultimately leading to improved patient outcomes.

OCTAPHARMA IS PROUD TO SUPPORT

The Peripheral Nerve Society 2018 Annual Meeting

Octapharma is one of the largest human plasma protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Our core business is the development and production of human plasma proteins from human plasma and human cell lines. Octapharma employs more than 7,600 people worldwide to support the treatment of patients in 113 countries with coagulation disorders, immune disorders, and other critical illnesses.
THE POTENTIAL TO TRANSFORM the treatment of hATTR amyloidosis

ON THE HORIZON FROM ALNYLAM

The landscape of hereditary ATTR (hATTR) amyloidosis is changing, and Alnylam is leading the way.

Visit us to learn more about recognizing the symptoms of hATTR amyloidosis and making a diagnosis.

For the latest news and updates, sign up at www.hATTRupdates.com.
PROUD TO BE
YEAR-ROUND SPONSORS
OF THE PERIPHERAL NERVE SOCIETY

VISIT CSL BEHRING AT TABLE #2

Learn about CSL Behring’s leadership in Ig therapy

• PATH, the largest CIDP trial
• A newly approved Ig therapy for CIDP
• One immunoglobulin portfolio, two impactful therapies, thousands of patients treated


CIDP = chronic inflammatory demyelinating polyneuropathy

Biotherapies for Life® is a registered trademark of CSL Behring LLC.
©2018 CSL Behring LLC
1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA
www.CSLBehring.com HIZ-0535-JUN18
Neuroinflammation

Abstract submission deadline
23 January 2019
Early registration deadline
10 April 2019

Visit our booth #29

Manufacturer of
PLASMA-DERIVED THERAPIES

Learn more at Kedrion.us
CARING FOR PEOPLE

For more than 75 years, Grifols has worked to improve the health and well-being of people around the world. We are committed to producing essential plasma-derived medicines for patients and to providing hospitals, pharmacies, and healthcare professionals with the tools, information, and services they need to deliver expert medical care.

GRIFOLS
pioneering spirit

Learn more about Grifols at www.grifols.com
2019 PNS ANNUAL MEETING
GENOA, ITALY • 22-26 JUNE
CENTRO CONGRESSI - PORTO ANTICO DI GENOVA